Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell CarcinomaShogo Shigeta, Christopher J. Kemp, Goldie Y.L. Lui et al.|Molecular Cancer Therapeutics|2021Cited by 30
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testingHeidi J. Gray, Carla Grandori, Payel Chatterjee et al.|npj Precision Oncology|2023Cited by 26
A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients.Astrid Margossian, Carla Grandori, Shalini Pereira et al.|Journal of Clinical Oncology|2021Cited by 4
Abstract 534: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilitiesGoldie Y.L. Lui, Carla Grandori, Anne B. Richardson et al.|Cancer Research|2021Cited by 4
Abstract PS4-01: Clinical and genomic correlation of a CLIA certified organoid based functional test in breast cancer patientsAstrid Margossian, Carla Grandori, Anne Richardson et al.|Cancer Research|2021Cited by 1